Syngene International, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹833 crore and net profit of ₹32 crore for the September 2026 quarter.
Syngene International (NSE: SYNGENE) closed at ₹451.70 on 20 Nov 2026, down 28.8% over the past year. Its market capitalisation is ₹18,234 crore and it trades at 68.6 times earnings.
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.